Explore the vast range of titles available.

Many ongoing changes are likely to have an impact on cancer research and care. For example, technological advances are rapidly changing the way cancer research is conducted, and the recently passed healthcare reform legislation has many implications for cancer care. Technological advances are altering the way cancer research is conducted and cancer care is delivered, and the recently passed healthcare reform legislation has many implications for cancer care. There is a growing emphasis on molecularly targeted therapies, information technology (IT), and patient-centered care, and clinical cancer research has become a global endeavor. At the same time, there are concerns about shrinking research budgets and escalating costs of cancer care. Considering such changes, the National Cancer Policy Forum (NCPF) of the Institute of Medicine held a National Cancer Policy Summit on October 25, 2010. The Summit convened key leaders in the cancer community to identify and discuss the most pressing policy issues in cancer research and cancer care. The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care is a summary of the summit. The report explores policy issues related to cancer research, the implementation of healthcare reform, delivery of cancer care, and cancer control and public health needs. Expert participants suggested many potential actions to provide patient-centered cancer care, to foster more collaboration, and to achieve other goals to improve research and care.

In our society's aggressive pursuit of cures for cancer, we have neglected symptom control and comfort care. Less than one percent of the National Cancer Institute's budget is spent on any aspect of palliative care research or education, despite the half million people who die of cancer each year and the larger number living with cancer and its symptoms. Improving Palliative Care for Cancer examines the barriers-scientific, policy, and social-that keep those in need from getting good palliative care. It goes on to recommend public- and private-sector actions that would lead to the development of more effective palliative interventions; better information about currently used interventions; and greater knowledge about, and access to, palliative care for all those with cancer who would benefit from it.

Inspired by the experience of art therapists who have pioneered work with people with cancer and including those who have experienced this devastating illness at first hand, this book acknowledges the outstanding work of the Corinne Burton Trust which has supported the development of art therapy services in hospices and clinics throughout.

Her detailed analysis of popular beliefs and behaviours reveals the compelling logic of personal decisions about health and healing. Experience and expectation, not fear and ignorance, shaped the health care choices of both cancer sufferers and the \"healthy\" public. A close examination of three unconventional practitioners in Ontario demonstrates the importance and vitality of alternative medicine. By presenting treatment options that were congenial and plausible to cancer sufferers, these healers contested the authority of conventional medicine. An investigation of government cancer care policy, particularly the activities of Ontario's Commission for the Investigation of Cancer Remedies, exposes the difficulties of defining legitimate health care and the limits of state support for the medical profession.

Psycho-oncology was written to assist oncologists, physicians, psychiatrists and other mental health clinicians, and hospital chaplains in understanding and offering supportive treatment to the more than 40% of individuals who will receive a cancer diagnosis during their lifetime.

Objective: To review our experience with cancer of prostate management, highlighting the mode of presentation, method of diagnosis, and the treatment outcome. Methods: Medical records of patients managed for cancer of prostate were retrospectively reviewed over a 10-year period. Relevant information which included the year of diagnosis, age at presentation, mode of presentation, digital rectal examination (DRE) findings, ultrasound (USS) assessment of the prostate, the prostate-specific antigen (PSA) value, the histology report, treatment offered and the outcome were extracted. Data were analyzed with SPSS version 11 software. Results: A total of 192 patients were managed for cancer of prostate within the study period but only 90 case notes were available for analysis. There was a 7.7 fold increase in the incidence of cancer of prostate. The mean age (±SD) at presentation was 68.4 (±10.1) years with an age range of 47-91 years and the peak incidence occurred in the seventh and eighth decades of life. The mean duration of symptoms prior to presentation was 10.3 (±17.1) months. A total of 66.7% of cases presented within 6 months of the onset of symptoms as against 14.4% of cases presented after a year. Majority of cases (88.9%) presented as locally advanced or metastatic disease and only 4.4% of cases were found incidentally. Only 38.9% had histologic confirmation of the diagnosis before management was instituted. DRE gave a false negative finding in 28.6% in this study. The sensitivity and false negative value of USS was 50% each and 3.3% had PSA within normal value. Bilateral orchidectomy was offered to 64 of 90 (71.1%) and the cancer related death (CRD) was 15.6%. The maximum follow-up period was 36 months in this study and 36.9% are still attending follow-up clinic. Conclusion: There was an apparent increase in the incidence of cancer of prostate from the present study with majority still presenting with advanced disease. The sensitivity of DRE was high; this probably accounted for the treatment without establishing the histologic diagnosis in majority of the cases. Such a practice of clinical diagnosis alone should be discouraged. Objectif: Pour consulter notre expérience avec le cancer de la prostate gestion, mise en évidence du mode de présentation, méthode de diagnostic et le résultat du traitement. Méthodes: Les dossiers médicaux des patients gérés pour le cancer de la prostate ont été examinées a posteriori sur une période de 10 ans. Des informations pertinentes qui inclus l'année de diagnostic, l'âge, à la présentation, le mode de présentation, les conclusions numérique toucher rectal (TR), évaluation des ultrasons (USS) de la prostate, la valeur de l'antigène prostatique spécifique (PSA), le rapport de l'histologie, traitement offerts et les résultats ont été extraites. Les données ont été analysées avec SPSS version 11 logiciels. Résultats: Un total de 192 patients étaient gérés pour le cancer de la prostate au sein de la période d'étude, mais seulement 90 notes de cas étaient disponibles pour l'analyse. Il y avait une augmentation de 7,7 pli dans l'incidence du cancer de la prostate. La moyenne d'âge (±SD) à la présentation était 68.4 (±10.1) ans avec une tranche d'âge de 47-91 ans et l'incidence de pointe s'est produite dans les décennies septième et huitième de la vie. La durée moyenne de symptômes avant à la présentation était 10.3 (±17.1) mois. Un total de 66,7% de cas présentées dans un délai de 6 mois à compter de l'apparition des symptômes contre 14,4% des cas présentés après un an. La majorité des cas (88,9%), présenté comme une maladie localement avancée ou METASTATIQUE et seulement 4,4% des cas ont été trouvés par ailleurs. Seulement 38,9% avaient histologiques confirmation du diagnostic avant de gestion a été instituée. Y a donné une fausse conclusion négative de 28,6% dans cette étude. La valeur négative de l'USS, sensibilité et false avait 50% chacun et 3,3% PSA au sein de la valeur normale. Orchidectomy bilatéral a été offerte à 64 de 90 (71,1%) et le cancer liés à la mort (CRD) était 15,6%. La période maximale de suivi a été 36 mois dans cette étude et 36,9% fréquentent toujours suivi clinique. Conclusion: Il y a une augmentation apparente de l'incidence du cancer de la prostate de la présente étude à majorité présentant encore les avancé de la maladie. La sensibilité de l'évaluation était élevée; cela représentait probablement le traitement sans établir le diagnostic histologiques dans la majorité des cas. Une telle pratique de diagnostic clinique seul devrait être déconseillée.

With the unique chemical and physical properties of cold atmospheric plasmas enabling their recent applications in biomedicine, plasma medicine has established itself as a new scientific field, combining plasma physics, engineering, medicine, and bioengineering. This book provides a comprehensive introduction to the fundamentals of the non-thermal plasmas and plasma devices used in plasma medicine. Several chapters are devoted to the analysis of the mechanisms of plasma interaction with cancer and normal cells, including a description of the mechanism of plasma selectivity. As a revised and significantly expanded second edition, this text includes a detailed description of non-invasive modality, new in vivo work and adaptive plasma written by experts in these areas. This reference text also provides an up-to-date description of the field, the primary challenges and future directions. Part of IOP Series in Plasma Physics.

Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy: Gastrointestinal Cancer provides a practical overview of this rapidly advancing field.Comprehensive yet concise, this easy-access resource by Dr. Milind Javle of MD Anderson Cancer Center and Dr.Mitesh J.